Author

J. N. Rich

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 5 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

J. D. Lathia· 2 shared R. C. Gimple· 2 shared T. Koga· 2 shared A. E. Clark· 1 shared A. Kashyap· 1 shared A. Khan· 1 shared A. L. Sarver· 1 shared A. Lauko· 1 shared

Activity by Year

2021-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. D. Lathia

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Stable isotope tracing in human plasma-like medium reveals metabolic and immune modulation of the glioblastoma microenvironment

M. R. Savani, M. El Shami, L. C. Gattie, B. C. Smith, W. H. Hicks, S. S. Oken, L. G. Zacharias, M. S. Martin-Sandoval, E. Y. Montgomery, Y. Xiao, D. D. Shi, J. N. Rich, T. E. Richardson, P. O. Zinn, B. C. Lega, , K. G. Abdullah

This paper develops an in vitro method using human plasma-like medium to study glioma metabolism and immune interactions, revealing microenvironment-dependent metabolic features and immune responses.

bioRxiv · May 29, 2023Cancer Biology

WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma

K. Mitchell, S. Shakya, S. Arora, S. A. Sprowls, D. J. Silver, C. M. Goins, L. Wallace, G. Roversi, R. Schafer, K. Kay, T. E. Miller, A. Lauko, A. Kashyap, J. D. Kass, E. E. Mulkearns-Hubert, , J. D. Lathia

This study identifies WDR5 as an essential epigenetic regulator in therapy-resistant glioblastoma cancer stem cells and shows that WDR5 inhibitors disrupt CSC maintenance and tumor growth.

bioRxiv · Sep 20, 2021Cancer Biology

Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma.

A. Sen, B. C. Prager, D. Park, Z. Zhu, R. C. Gimple, J. A. Bernatchez, S. Beck, A. E. Clark, J. L. Siqueira-Neto, J. N. Rich, G. P. McVicker

This study identifies genes with allele-specific expression in glioblastoma stem cells, finding SLFN11 loss linked to drug resistance and susceptibility to Zika virus.

bioRxiv · Jun 22, 2021Cancer Biology

HAUSP Stabilizes SOX2 through Deubiquitination to Maintain Self-renewal and Tumorigenic Potential of Glioma Stem Cells

Z. Huang, K. Zhai, Q. Wu, X. Fang, Q. Huang, W. Tao, J. D. Lathia, J. S. Yu, J. N. Rich, S. Bao

This study identifies HAUSP as a deubiquitinase that stabilizes SOX2 in glioma stem cells, maintaining their self-renewal and tumorigenic potential, and shows that targeting HAUSP can enhance GBM treatment.

bioRxiv · Jun 9, 2021 · PreprintCancer Biology

PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response

J. Li, M. M. Kaneda, J. Ma, M. Li, K. Patel, T. Koga, A. L. Sarver, F. Furnari, B. Xu, S. Dhawan, J. Ning, H. Zhu, A. Wu, G. You, T. Jiang, , C. C. Chen

The paper identifies PI3Kγ as a driver of microglia/macrophage accumulation in glioblastoma, showing its inhibition enhances temozolomide response in preclinical models.

Proceedings of the National Academy of Sciences · Apr 12, 2021Peer-reviewedCancer Biology

Targeting Glioblastoma Signaling and Metabolism with A Re-Purposed Brain-Penetrant Drug

J. Bi, A. Khan, J. Tang, S. Wu, W. Zhang, R. C. Gimple, T. Koga, A. M. Armando, S. Miki, H. Yang, B. Prager, E. J. Curtis, D. A. Wainwright, F. B. Furnari, J. N. Rich, , P. S. Mischel

This study identifies fluoxetine as a potential therapy for glioblastoma by inhibiting SMPD1 and enhancing temozolomide efficacy, with real-world evidence suggesting improved survival.

bioRxiv · Mar 16, 2021Cancer Biology